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ABSTRACT
BACKGROUND: An increased interarm systolic blood pressure difference is an easily determined physical
examination !nding. The relationship between interarm systolic blood pressure difference and risk of future
cardiovascular disease is uncertain. We described the prevalence and risk factor correlates of interarm
systolic blood pressure difference in the Framingham Heart Study (FHS) original and offspring cohorts and
examined the association between interarm systolic blood pressure difference and incident cardiovascular
disease and all-cause mortality.
METHODS: An increased interarm systolic blood pressure difference was de!ned as !10 mm Hg using the
average of initial and repeat blood pressure measurements obtained in both arms. Participants were fol-
lowed through 2010 for incident cardiovascular disease events. Multivariable Cox proportional hazards
regression analyses were performed to investigate the effect of interarm systolic blood pressure difference
on incident cardiovascular disease.
RESULTS: We examined 3390 (56.3% female) participants aged 40 years and older, free of cardiovascular
disease at baseline, mean age of 61.1 years, who attended a FHS examination between 1991 and 1994
(original cohort) and from 1995 to 1998 (offspring cohort). The mean absolute interarm systolic blood
pressure difference was 4.6 mm Hg (range 0-78). Increased interarm systolic blood pressure difference was
present in 317 (9.4%) participants. The median follow-up time was 13.3 years, during which time 598
participants (17.6%) experienced a !rst cardiovascular event, including 83 (26.2%) participants with
interarm systolic blood pressure difference !10 mm Hg. Compared with those with normal interarm
systolic blood pressure difference, participants with an elevated interarm systolic blood pressure difference
were older (63.0 years vs 60.9 years), had a greater prevalence of diabetes mellitus (13.3% vs 7.5%,), higher
systolic blood pressure (136.3 mm Hg vs 129.3 mm Hg), and a higher total cholesterol level (212.1 mg/dL
vs 206.5 mg/dL). Interarm systolic blood pressure difference was associated with a signi!cantly increased
hazard of incident cardiovascular events in the multivariable adjusted model (hazard ratio 1.38; 95% CI,
1.09-1.75). For each 1-SD-unit increase in absolute interarm systolic blood pressure difference, the hazard
ratio for incident cardiovascular events was 1.07 (95% CI, 1.00-1.14) in the fully adjusted model. There was
no such association with mortality (hazard ratio 1.02; 95% CI 0.76-1.38).
CONCLUSIONS: In this community-based cohort, an interarm systolic blood pressure difference is common
and associated with a signi!cant increased risk for future cardiovascular events, even when the absolute
difference in arm systolic blood pressure is modest. These !ndings support research to expand clinical use
of this simple measurement.
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CLINICAL RESEARCH STUDY
An increased interarm systolic blood pressure difference is
usually de!ned as 10 mm Hg or greater1,2 and can be found
in up to 24% of healthy individuals.3-6 It has been suggested
that identi!cation of interarm systolic blood pressure dif-
ference is crucial for appropriate identi!cation and treatment
of hypertension,7-9 for clinical decision-making and sur-
veillance.1,10-13 Interarm systolic
blood pressure differences have
been studied in patients in primary
care settings,14-16 in patients with
various manifestations of vascular
disease,17-19 and in population-
based cohorts.3,6,16 It has been
found to correlate with classic and
novel cardiovascular risk factors
and may be predictive of cardio-
vascular events. Nevertheless, data
on the epidemiology of interarm
systolic blood pressure difference
are relatively scarce.3,6,16,17 While
an association between interarm
systolic blood pressure difference and mortality was noted in
3 small prospective studies and a meta-analysis that pooled
data from 20 older studies,14,15,17,18,20 the evidence for an
association with cardiovascular disease is less consistent.20
The objectives of this study were to describe the distribu-
tion of interarm systolic blood pressure difference and risk
factor correlates in the Framingham Heart Study (FHS)
original and offspring cohorts and to determine the associ-
ation between interarm systolic blood pressure difference
and incident cardiovascular events and all-cause mortality.
METHODS
Study Participant Sample
Methods of recruitment have been described previously for
participants from the original cohort and the offspring study
cohort of the FHS.21,22
From the original FHS cohort of 5209 that was recruited
in 1948,23 1026 men and women attended an FHS exami-
nation between 1991 and 1994. There also were 3532 men
and women from the offspring study cohort who attended
the sixth offspring cycle examination from 1995 to 1998. Of
the 4558 total original and offspring cohort participants, 494
were excluded because they did not have a blood pressure
measurement in both arms. Of the remaining participants,
66 participants <40 years old and 608 with prevalent car-
diovascular disease were excluded. The Institutional Review
Board at Boston University Medical Center approved the
examination content, and informed consent was obtained
from study participants at the time of their examination.
Interarm Systolic Blood Pressure Measurement
For the purpose of calculating the interarm systolic blood
pressure difference, brachial systolic blood pressure mea-
surements were obtained as part of an ankle-brachial index
measurement by trained technicians according to a standard
protocol after participants lay supine for at least 5 minutes.
Measurements were taken in the sequence of right arm, left
arm, right ankle, and left ankle and repeated twice. If the
initial and repeat blood pressure differed by >10 mm Hg at
any site, a third measurement was taken. When 2 blood
pressure measurements were ob-
tained in the same arm, the
average blood pressure in that arm
was used. The interarm systolic
blood pressure difference was
de!ned as the absolute difference
between the single or average
blood pressure measurements in
each arm. An increased interarm
systolic blood pressure difference
was de!ned as interarm systolic
blood pressure difference !10
mm Hg.14,18 The maximal differ-
ence between arms was used.
De!nition of Incident Cardiovascular Disease
Events and Mortality
Participants were followed through 2010 for the !rst inci-
dent cardiovascular event, de!ned as coronary heart disease
(ie, a fatal coronary event, recognized myocardial infarction
and unrecognized myocardial infarction, coronary insuf!-
ciency, or angina), a cerebrovascular event (ie, ischemic
stroke or transient ischemic attack), intermittent claudica-
tion,24 or congestive heart failure.25 An unrecognized
myocardial infarction was adjudicated when serial changes
on the electrocardiogram showed development of pathologic
Q waves and neither the participant nor the physician
considered the possibility of a myocardial infarction. Mor-
tality data were obtained by review of all medical records
including the last hospitalization, nursing home records,
personal physical records, and if needed, next-of kin in-
terviews along with death certi!cate evaluation. All car-
diovascular events and deaths in both the original cohort and
offspring participants were adjudicated by an end-point
committee of 3 senior investigators using the same criteria
and all available medical records. Ischemic stroke and
transient ischemic attack events were reviewed by a panel
of study neurologists.
De!nition of Risk Factor Covariates
Covariates were obtained at the same time as the interarm
systolic blood pressure difference measurement. Hyperten-
sion was de!ned as a blood pressure !140/90 mm Hg or the
use of antihypertension medications. Body mass index was
calculated as the participants’ weight in kilograms divided
by the participants’ height in meters squared. Diabetes
mellitus was considered present if the fasting glucose was
!126 mg/100 mL (offspring), a nonfasting glucose of !200
mg/dL (original cohort), or if the participant was receiving
CLINICAL SIGNIFICANCE
" Interarm systolic blood pressure differ-
ence (ISBPD) is associated with incident
cardiovascular events independent of
traditional cardiovascular risk factors in
a large community-based cohort.
" Measurement of blood pressure in both
arms is important both for accurate
blood pressure detection and for car-
diovascular risk strati!cation.
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treatment with insulin or oral hypoglycemic medications.
Total cholesterol was analyzed as a continuous variable.
Lipid-lowering therapy was entered into the model as a
separate binary variable. Participants were queried at each
examination about cigarette smoking, and current smoking
was de!ned as smoking at least one cigarette per day in the
year preceding the examination. The 10-year Framingham
risk score for general cardiovascular disease was calculated
for each participant.26
Statistical Analysis
Descriptive statistics were generated. Continuous measures
were summarized using mean and SD. Categorical traits
were summarized using percentages. We standardized
interarm systolic blood pressure difference (ISBPD) to
mean # 0 and SD # 1 because this measure is skewed to
the right. Hazard ratios (HRs) for continuous ISBPD were
presented for every 1-SD-unit increase in blood pressure.
The main exposure, ISBPD, was !rst analyzed as a binary
variable (ie, <10 mm Hg and !10 mm Hg); then as a
3-level ordinal variable (<10 mm Hg vs 10 to <15 mm Hg
and !15 mm Hg), and then as a continuous trait. We tested
for linear trend in the hazards across the 3-level ordinal
variable. Two-sample t-test with pooled variance or unequal
variance as indicated was used to compare means between
participants who had ISBPD !10 mm Hg versus those with
ISBPD <10 mm Hg. The chi-squared test was used to
compare categorical traits. Age- and sex-adjusted time to
!rst cardiovascular event was analyzed using Kaplan-Meier
plots and evaluated using the log-rank chi-squared test.
Next, after con!rming the validity of the Cox proportional
hazards regression assumptions, 2 Cox models were !tted
with ISBPD <10 mm Hg as the referent category. The !rst
model adjusted for the following variables: age, sex, hy-
pertension, total cholesterol level, high-density lipoprotein
cholesterol, cholesterol treatment, presence or absence of
diabetes mellitus, and smoking status; and the second model
adjusted for the 10-year Framingham risk score for general
cardiovascular disease.26 We also assessed for linear trend
using the 3-category ordinal ISBPD variable (ie, ISBPD<10
mm Hg, 10 to <15 mm Hg, and !15 mm Hg). Furthermore,
similar models were !tted, accounting for familial correla-
tions between the original and offspring cohorts. We used
generalized estimating equations to account for the familial
correlations within our dataset. Similar analysis approaches
were used restricting the sample to hypertensive participants
and also using mortality as the outcome.
The predictive utility of the Cox model was examined by
comparing the c-statistic. The incremental effect of adding
ISBPD to the Framingham risk score for predicting cardio-
vascular outcomes was evaluated with the use of category-
based net reclassi!cation improvement index (NRI).27 The
NRI is used to assess how well an exposure “reclassi!es”
patients from one risk category to another. We calculated
NRI using an extension to survival analysis that employs
Kaplan-Meier estimates of event probabilities using cate-
gories: low risk (0 to<6%), intermediate risk (6% to 20%), or
high risk (>20%). A large NRI indicates that the additional
exposure causes a large improvement in reclassi!cation.
RESULTS
Our !nal study sample included 3390 participants; mean
age of 61.1 $ 11.3 years, 56.3% women, followed for an
average of 13.3 years. The median ISBPD was 3 (inter-
quartile range 2.6) mm Hg, and 317 (9.4%) participants had
an ISBPD !10 mm Hg (Table 1). The distribution of
Table 1 Age and Sex-Adjusted Comparison of Baseline Variables by Interarm Systolic Blood Pressure Difference
Variable ISBPD <10 mm Hg (n # 3073*) ISBPD !10 mm Hg (n # 317*) P-Value
Age† 60.9 (11.3) 63.0 (11.5) .002
Male (%)† 1343 (43.7) 137 (43.2) .87
Body mass index kg/m2 27.4 (4.8) 29.6 (6.2) <.001
SBP mm Hg 129.3 (19.3) 136.3 (20.3) <.001
DBP mm Hg 74.9 (9.8) 76.3 (9.9) .02
Hypertension (%) 1249 (40.6) 184 (58.0) <.001
HTN treatment (%) 789 (25.7) 137 (43.6) <.001
Total cholesterol mg/dL 206.5 (39.3) 212.1 (40.2) .17
HDL cholesterol mg/dL 51.8 (16.2) 51.2 (16.9) .53
Triglycerides mg/dL 137.8 (135.2) 151.2 (105.8) .004
Lipid lowering treatment (%) 282 (9.2) 38 (12.0) .10
Diabetes mellitus (%) 229 (7.5) 42 (13.3) .003
Current cigarette use (%) 426 (13.9) 39 (12.3) .44
Ever cigarette use (%) 1384 (45.0) 137 (43.2) .54
Framingham 10-year risk score 12.3 (10.6) 15.2 (12.1) <.001
DBP # diastolic blood pressure; HDL # high-density lipoprotein; HTN # hypertension; ISBPD # interarm systolic blood pressure difference; SBP #
systolic blood pressure.
*Percentages were calculated from the available number of participants in a particular category.
†Not age- and sex-adjusted.
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systolic blood pressure difference between arms in the
sample is shown in Figure 1. There were 3073, 246, and
71 participants with ISBPD of <10 mm Hg, 10 to <15
mm Hg and !15 mm Hg, respectively.
Overall, 598 participants (17.6%) experienced a !rst
cardiovascular event, including 83 (26.2%) participants with
an increased ISBPD. The overall incidence rate of total
cardiovascular disease was 17.64 per 1000 person-years
(95% con!dence interval [CI], 16.25-19.11). Age- and
sex-adjusted Kaplan-Meier plots strati!ed by binary ISBPD
(<10 mm Hg vs !10 mm Hg) are shown in Figure 2 and
show that the ISBPD !10 mm Hg category had a
signi!cantly higher probability for incident cardiovascular
event than the ISBPD <10 mm Hg category (log-rank test
chi-squared # 18.2, P <.0001).
An ISBPD!10mmHgwas associated with a signi!cantly
increased hazard of incident cardiovascular events
in the multivariable adjusted Cox models (HR 1.38; 95%
CI, 1.09-1.75) (Table 2). There was no change in the hazard
with adjustment for Framingham risk score. In a multivariable
model, an ISBPD !15 mm Hg was associated with an
increased hazard of incident cardiovascular events (HR
1.47; 95% CI, 0.93-2.32). There was a statistically
signi!cant linear trend with increasing ISBPD category
(P # .009 in the multivariable adjusted model). An ISBPD
!10 mm Hg also was associated with a signi!cantly
increased hazard of incident cardiovascular events in a
subgroup analysis of 1433 hypertensive participants (HR
1.50; 95% CI, 1.14-1.97, in the multivariable model). In
similar analyses for total mortality, there were no signi!cant
associations (Table 2). For each 1-SD increase in absolute
ISBPD, the HR for incident cardiovascular events was 1.07
(95% CI, 1.00-1.14) in the multivariable-adjusted model
(Table 3). There was no signi!cant sex interaction with
ISBPD. Adjustment for familial clustering did not
materially alter the results.
We examined model performance and the utility of
ISBPD in reclassi!cation of overall risk for incident car-
diovascular disease. Both the c-statistic for a multivariable
model that included ISBPD and a multivariable model that
did not include ISBPD were 0.74 (95% CI, 0.72-0.76).
Category-based net reclassi!cation for improvement
changed signi!cantly with ISBPD (NRI 0.021; P # .02).
The net reclassi!cation is presented in Table 4.
DISCUSSION
In this large, prospective, community-based cohort of
middle-age men and women free of cardiovascular disease,
an increased ISBPD was found to be present in nearly 10%
of individuals, and is associated with increased levels of
traditional cardiovascular risk factors. Furthermore, an
increased ISBPD is associated with an increased risk for
incident cardiovascular events, independent of traditional
cardiovascular risk factors. This association is consistent
when ISBPD was examined as a binary and as a continuous
variable, and showed a positive linear trend across cate-
gories of increasing ISBPD. This is the !rst community-
based cohort study to show such an association.
While we did not examine the anatomical correlates of
increased ISBPD, our !ndings are consistent with previous
publications linking subclavian artery stenosis to increased
cardiovascular risk3,28 and are indirectly consistent with
studies linking increased ISBPD with subclavian artery
stenosis. Indeed, ISBPD >10 mm Hg has been shown to
have a high sensitivity,29,30 yet a low speci!city31 for an-
giographically signi!cant subclavian artery stenosis.
Furthermore, in 2 population-based studies, subclavian ar-
tery stenosis has been found to correlate with conventional
risk factors for atherosclerosis.6,16 While a recent meta-
analysis did not !nd a correlation between an ISBPD !15
Figure 1 Distribution of absolute interarm systolic blood
pressure difference.
Figure 2 Age- and sex-adjusted Kaplan-Meier plot for
incident cardiovascular events in 3390 participants with or
without an interarm systolic blood pressure difference (ISBPD)
!10 mm Hg (log-rank test chi-squared P <.0001).
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mm Hg and a known pre-existing diagnosis of cardiovas-
cular disease when pooling 6 studies,20 subclavian artery
stenosis has been shown to correlate with ischemic heart
disease as detected by stress myocardial single-photon
emission computed tomography.32
In 6743 participants free of clinical cardiovascular dis-
ease in the Multi-Ethnic Study of Atherosclerosis (MESA)
an ISBPD !15 mm Hg was found in 307 (4.5%) and
correlated with subclinical measures of cardiovascular dis-
ease.3 Consistent with our !ndings, the MESA participants
with an increased ISBPD tended to be older, more likely to
have diabetes mellitus and hypertension, and were more
obese than participants with a normal ISBPD. An increased
ISBPD was found to correlate with markers of atheroscle-
rosis including peripheral artery disease (ankle-brachial in-
dex %0.9), an increase in carotid intima-media thickness,
and a high coronary calcium score. Mortality and cardio-
vascular events were not assessed.
Several small prospective studies in cohorts of selected
participants and a single meta-analysis previously described
an association between ISBPD and both all-cause and car-
diovascular mortality,14,17,18,20 however, an association with
cardiovascular disease in those studies was inconsistent.20
In a prospective study of 230 hypertensive patients (mean
age 68.1 years) who were followed for a median of 9.8 years
in a primary care setting, 55 (23%) had an ISBPD !10 mm
Hg.14 An ISBPD !10 mm Hg was associated with incident
CV events and with all-cause mortality, and there also was
an increase of 5%-6% in the incidence of mortality for each
1-mm-Hg increase in ISBPD. In another prospective cohort
recruited from 2 clinics, 421 consecutive patients (mean age
62.9 years), 95% of whom were men, were followed for
a median of 5.6 years. Mortality was 31% and associated
with an increase in ISBPD.18 In contrast, overall mortality
in our study occurred in 12.2% over a longer period of time.
Incident cardiovascular disease was not reported in this
study. These 2 studies were small and selective, focusing on
patients with hypertension or renal disease, making them
less useful for drawing general conclusions. Adequately,
in the secondary analysis in the subset of our study partic-
ipants with hypertension, we observed a signi!cant associ-
ation between ISBPD and incident cardiovascular events.
Finally, in another study combining 3 cohorts, 1778 subjects
were recruited from both noninvasive vascular diagnostic
laboratories and the community, and followed for a median
of 9.4 years.17 In a fully adjusted model accounting for
cardiovascular risk factors and for baseline cardiovascular
disease, an ISBPD !15 mm Hg demonstrated only
increasing but not signi!cant hazards for cardiovascular
mortality (HR 1.43; 95% CI, 0.93-2.18). Incident cardio-
vascular disease was again not reported, the study popula-
tion was enriched with high-risk patients being evaluated
in vascular laboratories, and cause of death was adjudicated
based on death certi!cate data. As expected, our study
Table 3 Standardized ISBPD: Risk-factor-adjusted Relative
Risk of a First Cardiovascular Event According to ISBPD
Strati!cation HR (95% CI)* P-Value
MV adjusted† 1.07 (1.00-1.14) .04
Framingham 10 year risk score 1.08 (1.02-1.15) .02
CI # con!dence interval; HR # hazard ratio; ISBPD # interarm
systolic blood pressure difference; MV # multivariable.
*For every 1-SD-unit increase in blood pressure.
†Adjusted for age, sex, smoking status, diabetes mellitus, hyper-
tension, high-density lipoprotein cholesterol/total cholesterol ratio and
cholesterol treatment.






Primary analysis for ISBPD !10 mm Hg:
MV adjusted* <10 referent 1.00 1.00
!10 mm Hg 1.38 (1.09-1.75) 1.02 (0.76-1.38)
Framingham 10-year risk score <10 referent 1.00 1.00
!10 mm Hg 1.38 (1.09-1.75) 0.98 (0.72-1.33)
Analysis for ISBPD categories 10 to <15 mm Hg
and !15 mm Hg:
MV adjusted* <10 referent 1.00 1.00
10 to <15 mm Hg 1.36 (1.04-1.77) 0.99 (0.71-1.39)
!15 mm Hg 1.47 (0.93-2.32) 1.11 (0.62-1.99)
Trend P-value .009 .82
Framingham 10-year risk score <10 referent 1.00 1.00
10 to <15 mm Hg 1.32 (1.01-1.72) 0.95 (0.67-1.35)
!15 mm Hg 1.62 (1.02-2.56) 1.05 (0.57-1.95)
Trend P-value .005 .97
BP # blood pressure; CI # con!dence interval; CVD # cardiovascular disease; HR # hazard ratio; ISBPD # interarm systolic blood pressure difference;
MV # multivariable.
*Adjusted for age, sex, smoking status, diabetes mellitus, hypertension, high-density lipoprotein cholesterol/total cholesterol ratio, and cholesterol
treatment.
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participants were of lower risk, and it is not surprising that
our HR for cardiovascular events were lower. Our lower-
risk population also may have been underpowered to
detect a mortality association with ISBPD. Post hoc power
calculations revealed that with 489/3390 deaths, 50 of which
occurred in the ISBPD !10 mm Hg, we only had 22% and
76% power to detect HRs of 1.2 and 1.5, respectively. For
the association with mortality, our HR was low and not
signi!cant. Furthermore, of the deaths in our cohort, most
were not cardiovascular disease related, further limiting our
ability to assess an association with ISBPD.
Potential limitations of the present study include sequen-
tial, as opposed to simultaneous, blood pressure measure-
ments,2,7,33-35 and blood pressure measurements during one
encounter as opposed to an average of separate encoun-
ters.34,36,37 Nonetheless, in a cohort in which the prevalence
of ISBPD >10 mm Hg was 40%, the ISBPD was roughly
stable, despite repeated measurements,18 and in 2 studies
comparing sequential and simultaneous measurements, the
ISBPD differences were well below the 10 mm Hg threshold
that we have used.35,38 Given that our results have shown
signi!cant and consistent prognostic value, they are unlikely
to represent random variation. Furthermore, sequential blood
pressure measurement is the accepted method of measuring
arm blood pressures in clinical practice,39 making our results
clinically applicable. Strengths of the present study include
its large community-based sample, a comprehensive directly
measured covariate assessment, and validated cardiovascular
events and deaths. Finally, the signi!cant category-based net
reclassi!cation improvement index suggests statistically
signi!cant, albeit small, enhancement of incident cardio-
vascular event prediction beyond traditional risk factors by
considering ISBPD.
In conclusion, in this community-based cohort, an
ISBPD was common and was associated with a signi!cant
increase in risk for cardiovascular events even after adjust-
ment for cardiovascular risk factors. Even modest differ-
ences in clinically measured systolic blood pressures in
the upper extremities re"ect on cardiovascular risk. This
study supports the potential value of identifying the
ISBPD as a simple clinical indicator of increased cardio-
vascular risk. Blood pressure is easily obtained in an of!ce
setting, and our !ndings support recommendations for
measurement of blood pressure in both arms, both for ac-
curate blood pressure detection and for detection of ISBPD.
Our !ndings support research to expand clinical use of this
simple measurement.
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